Lundberg, A. S., Baer, M. R., Chau, M., Erba, H. P., Dressel, A. L., Ajami, A. M., & Capizzi, R. L. (2008). Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy. In Journal of Clinical Oncology (Vol. 26, pp. 13536–13536). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2008.26.15_suppl.13536

Lundberg, A. S., M. R. Baer, M. Chau, H. P. Erba, A. L. Dressel, A. M. Ajami, and R. L. Capizzi. “Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy.” In Journal of Clinical Oncology, 26:13536–13536. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.13536.

Lundberg AS, Baer MR, Chau M, Erba HP, Dressel AL, Ajami AM, et al. Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 13536–13536.

Lundberg, A. S., et al. “Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2008, pp. 13536–13536. Crossref, doi:10.1200/jco.2008.26.15_suppl.13536.

Lundberg AS, Baer MR, Chau M, Erba HP, Dressel AL, Ajami AM, Capizzi RL. Blast cells from patients treated for secondary AML (sAML) show less P-glycoprotein (Pgp)-mediated efflux of amonafide compared to daunorubicin: Implications for therapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008. p. 13536–13536.